

F. No. 12(7)/2017/DP/NPPA/Div.II / Vol-IV  
**National Pharmaceutical Pricing Authority**

**Subject: Minutes of the 32<sup>nd</sup> meeting of Multidisciplinary Committee of Experts held on 23.05.2021 at 12:00 noon in NPPA**

32<sup>nd</sup> meeting of the “Multidisciplinary Committee of Experts” was held on 23.05.2021 under the Convenorship of Sh. N.I. Chowdhury, Adviser (Cost), in NPPA. The following members attended the meeting through video conferencing:-

1. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, Gol & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi
2. Dr. Rakesh K. Singh, Assoc. Professor, NIPER, Raebareli
3. Shri A. K. Pradhan, Dy. Drugs Controller, CDSCO
4. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoeia Commission
5. Dr. J.J. Cherian, Scientist D, IMCR, New Delhi

The following officers of NPPA attended and presented the cases to the Committee

1. Sh. S. S. Ojha, Jt. Director (Pricing), NPPA
2. Sh. Prasenjit Das, Deputy Director (Pricing), NPPA

**1. Agenda No. 1 - Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Ivabradine Hydrochloride eq. to Ivabradine 7.5 mg + Metoprolol Tartrate 25 mg for M/s Archimedis Healthcare Pvt. Ltd. (manufacturer) and M/s Lupin Ltd. (marketer)**

1.1 The Committee deliberated upon the matter in detail and recommended the retail price of each film coated tablet containing Ivabradine Hydrochloride eq. to Ivabradine 7.5 mg + Metoprolol Tartrate 25 mg for M/s Archimedis Healthcare Pvt. Ltd. (manufacturer) and M/s Lupin Ltd. (marketer) at Rs. 20.68 per tablet excluding GST as detailed below:

Particulars	Source	Price in Rs (excluding GST)
Calculated price of Ivabradine 5 mg + Metoprolol 25 mg tablet	As per para 4 based on	15.75
Less: Calculated price of Ivabradine 5 mg tablet	September 2020 data	15.13
Add: Calculated price of Ivabradine 7.5 mg tablet		20.06
Worked out retail price		20.68

**2. Agenda No. 2 - Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Darunavir Ethanolate eq. to Darunavir IP 800 mg +**

**Ritonavir IP 100 mg for M/s Hetero Labs Ltd. (manufacturer) and M/s Cipla Ltd. (marketer)**

2.1 The Committee deliberated upon the matter in detail and recommended the retail price of each film coated tablet containing Darunavir Ethanolate eq. to Darunavir IP 800 mg + Ritonavir IP 100 mg for M/s Hetero Labs Ltd. (manufacturer) and M/s Cipla Ltd. (marketer) at Rs. 190.44 per tablet excluding GST as detailed below:

<b>Sl. No.</b>	<b>Company</b>	<b>Price To Retailer (PTR) as per Fom-V submitted by the company</b>	<b>PTR per tablet</b>
1	Hetero Healthcare Ltd	Rs. 5109.29 per 30 tablet	Rs.170.30
2	Emcure Pharmaceuticals Ltd	Rs. 4741.20 per 30 tablet	Rs. 158.04
Therefore, average PTR			Rs. 164.17
Add: 16% retailer margin			Rs. 26.27
Worked out retail price per tablet			Rs. 190.44

**3. Agenda No. 3 – Application by M/s Otsuka Pharmaceuticals India Pvt. Ltd for separate price under Para 11(3) of DPCO 2013 with respect to Metronidazole Injection IP (0.5% w/v) 100ml in Non-glass pack having Special features**

3.1 The Committee deliberated upon the matter in detail and decided that the M/s Otsuka Pharmaceuticals Pvt. Ltd be directed to make demonstration before the Committee in its next meeting along with the justification. The Committee also directed to make further analysis on the matter and place in the next meeting.

**4. Agenda No. 4 - Application by M/s Otsuka Pharmaceuticals India Pvt. Ltd for separate price under Para 11(3) of DPCO 2013 with respect Mannitol Injection 20% in Non-glass pack having Special features**

4.1 The Committee deliberated upon the matter in detail and decided that the M/s Otsuka Pharmaceuticals Pvt. Ltd be directed to make demonstration before the Committee in its next meeting along with the justification. The Committee also directed to make further analysis on the matter and place in the next meeting.

**5. Agenda No. 5 - Application by M/s Otsuka Pharmaceuticals India Pvt. Ltd for separate price under Para 11(3) of DPCO 2013 with respect Dextrose Injection (25% w/v) 100 ml in Non-glass pack having Special features**

5.1 The Committee deliberated upon the matter in detail and decided that the M/s Otsuka Pharmaceuticals Pvt. Ltd be directed to make demonstration before the Committee in its next meeting along with the justification. The Committee also directed to make further analysis on the matter and place in the next meeting.

The meeting ended with a vote of thanks to all.

Sd/-  
(S. S. Ojha)  
Director (Pricing)

Copy to:  
All members of the Committee.





